Abstracts tagged "Lupus and genetic disorders"

Abstract Number: 2348 • 2017 ACR/ARHP Annual Meeting
A New Cause of Mendelian Lupus Due to IKZF1 Mutation Underlines the B Cell Landscape Heterogeneity in Monogenic Lupus
Alexandre Belot^1,2, Cecile Frachette³, Omarjee Sulliman Ommar², Anne-Laure Mathieu², Thibault Andrieu², Paul Mondier², Gillian Rice⁴, Heloise Reumaux⁵, David Launay^6,7, Marc Lambert^8,9, Guillaume Lefevre¹⁰, Nicole Fabien¹¹, Christophe Malcus¹², Isabelle Rouvet¹³, Emilie Chopin¹³, Anne-Sophie Michallet¹⁴, Thierry Defrance¹⁴, Thierry Walzer¹⁴ and Yanick J Crow¹⁵, ¹Pediatric Rheumatology Unit, HFME, Hospices Civils de Lyon, Bron, France, ²U1111, INSERM, Lyon, France, ³Hospices Civils de Lyon, Bron, France, ⁴Manchester Academic Health Science Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁵Pediatric Rheumatology, CHRU Lille, Lille, France, ⁶LIRIC, INSERM UMR 995, Lille, France, ⁷Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ⁸Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁹Medecine Interne Lilloise, Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Lille, France, ¹⁰Internal Medicine, Lille University Hospital, Lille, France, ¹¹Immunology Department, UF d'Autoimmunité, Immunology Department, CHU de Lyon HCL- GH Sud, Lyon, France, ¹²Cellular Immunology Department - Laboratoire d'immunologie cellulaire, Groupement Hospitalier Edouard Herriot, Lyon, France, ¹³Cellular Biotechnology Department, Centre de biologie et pathologie Est, Hospices civils de Lyon, Lyon, France, ¹⁴International Center for Infectiology Research - CIRI, Lyon, France, ¹⁵Institut Imagine, Paris, France
Background/Purpose: Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].